- Home
- AXL vs CGEM Comparison
AXL vs CGEM Comparison
Compare AXL & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXL
- CGEM
- Stock Information
- Founded
- AXL 1994
- CGEM 2016
- Country
- AXL United States
- CGEM United States
- Employees
- AXL N/A
- CGEM N/A
- Industry
- AXL Auto Parts:O.E.M.
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- AXL Consumer Discretionary
- CGEM Health Care
- Exchange
- AXL Nasdaq
- CGEM Nasdaq
- Market Cap
- AXL 487.5M
- CGEM 490.3M
- IPO Year
- AXL 1999
- CGEM 2021
- Fundamental
- Price
- AXL $4.33
- CGEM $7.77
- Analyst Decision
- AXL Hold
- CGEM Strong Buy
- Analyst Count
- AXL 8
- CGEM 4
- Target Price
- AXL $6.38
- CGEM $33.50
- AVG Volume (30 Days)
- AXL 3.0M
- CGEM 458.7K
- Earning Date
- AXL 05-02-2025
- CGEM 05-08-2025
- Dividend Yield
- AXL N/A
- CGEM N/A
- EPS Growth
- AXL N/A
- CGEM N/A
- EPS
- AXL 0.18
- CGEM N/A
- Revenue
- AXL $5,929,300,000.00
- CGEM N/A
- Revenue This Year
- AXL N/A
- CGEM N/A
- Revenue Next Year
- AXL $0.27
- CGEM N/A
- P/E Ratio
- AXL $24.62
- CGEM N/A
- Revenue Growth
- AXL N/A
- CGEM N/A
- 52 Week Low
- AXL $3.00
- CGEM $6.85
- 52 Week High
- AXL $7.98
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- AXL 64.56
- CGEM 44.72
- Support Level
- AXL $4.04
- CGEM $7.70
- Resistance Level
- AXL $4.42
- CGEM $8.97
- Average True Range (ATR)
- AXL 0.21
- CGEM 0.49
- MACD
- AXL 0.12
- CGEM -0.01
- Stochastic Oscillator
- AXL 92.21
- CGEM 18.37
About AXL American Axle & Manufacturing Holdings Inc.
American Axle & Mfg Holdings Inc is engaged in manufacturing, engineering, designing, and validation of driveline systems and related components and chassis modules for light trucks, SUVs, crossover vehicles, passenger cars, and commercial vehicles. The company's segment includes Driveline and Metal Forming. It generates maximum revenue from the Driveline segment.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.